Top Suppliers:I want be here
Related CAS#:
1614-12-6 105026-59-3
105026-61-7 132195-09-6
144146-59-8 144141-11-7
144140-24-9 144139-44-6
144146-62-3 56403-26-0
2248324-04-9 1158522-08-7
940364-43-2 134104-43-1
131615-57-1 6906-52-1
2639458-20-9 930439-75-1
1018584-77-4 1375289-11-4

1614-12-6

1614-12-6 structure
1614-12-6 structure
Name 1-Aminobenzotriazole
Synonyms MFCD00132902
1-Benzotriazolamine,ABT
benzotriazol-1-amine
1H-1,2,3-Benzotriazol-1-amine
1-Benzotriazolamine
1H-Benzo[d][1,2,3]triazol-1-amine
1-Aminobenzotriazole
1H-Benzotriazol-1-amine
Description 1-Aminobenzotriazole is a nonspecific and irreversible inhibitor of cytochrome P450 (P450).
Related Catalog
Target

P450[1]

In Vitro 1-Aminobenzotriazole (ABT) alone significantly increases the expression levels of CYP2B6 in two different hepatocytes (7.3- and 10.8-fold, respectively). Upon co-treatment with 1-Aminobenzotriazole, the induction of CYP2B6 expression by CITCO or rifampin is potentiated: 12.6- and 4.0-fold for CITCO as well as 3.9- and 2.5-fold for rifampin. 1-Aminobenzotriazole has a greater potentiation effect on CITCO than on rifampin. 1-Aminobenzotriazole alone increases the expression levels of CYP3A4 in tow different hepatocytes (by 2.0- and 3.8-fold). Upon co-treatment with 1-Aminobenzotriazole, the effects of CITCO on CYP3A4 expression levels are potentiated by 3.8- and 6.0- fold as compare to cells treated with CITCO alone[1]. 1-Aminobenzotriazole (ABT) (1 mM) shows pronounced (~95%) inhibition of the formation of N-acetylprocainamide compare with the control without 1-Aminobenzotriazole[2].
In Vivo Oral 1-Aminobenzotriazole (ABT) (100 mg/kg, 2 h predose) decreases the clearance of intravenous procainamide (45%) in rats, accompanied by a decreased N-acetylprocainamide-to-procainamide ratio in urine (0.74 versus 0.21) and plasma (area under the curve ratio 0.59 versus 0.11). The urinary recovery of procainamide increases from 18 to 30%, whereas the recovery of N-acetylprocainamide in urine decreases from 13.3 to 6.5% with 1-Aminobenzotriazole[2]. Pretreatment of rats with 100 mg/kg oral 1-Aminobenzotriazole (ABT) administered 2 hours before a semisolid caloric test meal markedly delays gastric emptying. 1-Aminobenzotriazole also increases stomach weights by 2-fold[3].
Cell Assay Freshly isolated human hepatocytes are used in this study. Briefly, hepatocytes are placed in serum-free Williams’ E media containing 0.1 μM dexamethasone, 10 μg/mL gentamicin, 15 mM HEPES, 2 mM L-glutamine, and 1% ITS. Cells are incubated for 10 hr at 37°C in an atmosphere containing 5% CO2. After recovery, the hepatocytes are treated with media containing CITCO (100 nM), rifampin (10 μM) or vehicle (ethanol), with or without 1-Aminobenzotriazole (ABT) (1 mM) for 72 hr[1].
Animal Admin Male Sprague-Dawley rats (0.26 to 0.30 kg, n=3 per treatment) receive an oral dose of 1-Aminobenzotriazole (ABT) (100 mg/kg, 2 mL/kg) 2 h before a single intravenous bolus of procainamide (10 mg/kg, 2 mL/kg). The control group receives only the intravenous bolus of procainamide without 1-Aminobenzotriazole pretreatment. The vehicle for both 1-Aminobenzotriazole and procainamide is 10% dimethylacetamide/90% water (v/v). Rats are fed 4 h after dosing, and serial blood samples are collected at 0.03, 0.17, 0.25, 0.5, 1, 2, 4, and 6 h postdose. Blood samples are centrifuged using tubes containing K3-EDTA as the anticoagulant to obtain plasma. Urine samples are also collected over 24 h postdose. Plasma and urine samples are frozen at -20°C until analysis[2].
References

[1]. Yang K, et al. Induction of CYP2B6 and CYP3A4 expression by 1-aminobenzotriazole (ABT) in human hepatocytes. Drug Metab Lett. 2010 Aug;4(3):129-33.

[2]. Sun Q, et al. 1-Aminobenzotriazole, a known cytochrome P450 inhibitor, is a substrate and inhibitor of N-acetyltransferase. Drug Metab Dispos. 2011 Sep;39(9):1674-9.

[3]. Stringer RA, et al. 1-Aminobenzotriazole modulates oral drug pharmacokinetics through cytochrome P450 inhibition and delay of gastric emptying in rats. Drug Metab Dispos. 2014 Jul;42(7):1117-24.
Density 1.5±0.1 g/cm3
Boiling Point 319.3±25.0 °C at 760 mmHg
Melting Point 81-84 °C(lit.)
Molecular Formula C6H6N4
Molecular Weight 134.139
Flash Point 146.9±23.2 °C
Exact Mass 134.059250
PSA 56.73000
LogP 0.75
Vapour Pressure 0.0±0.7 mmHg at 25°C
Index of Refraction 1.774
Water Solubility slightly soluble
Symbol GHS07
GHS07
Signal Word Warning
Hazard Statements H315-H319-H335
Precautionary Statements P261-P305 + P351 + P338
Personal Protective Equipment dust mask type N95 (US);Eyeshields;Gloves
Hazard Codes Xi: Irritant;
Risk Phrases R36/37/38
Safety Phrases S26-S36-S37/39
RIDADR NONH for all modes of transport
WGK Germany 3
HS Code 2933990090
HS Code 2933990090
Summary 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Chemsrc provides CAS#:1614-12-6 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 1614-12-6 | Chemsrc address: https://www.chemsrc.com/en/baike/441466.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved